GlassScriptPhysician profile
Rasik B Parmar
NPI 1144288721
$7,435.29
in general payments reported to CMS, 2019-2025
35 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $711 · 2021: $1,255 · 2022: $1,339 · 2023: $951 · 2024: $1,019 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,434.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,880.41 | 2021-2025 | |
| Pfizer INC. | $745.34 | 2019-2025 | |
| Lundbeck LLC | $530.24 | 2023-2025 | Vyepti |
| Eisai INC. | $478.56 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $466.26 | 2022-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $397.53 | 2019-2024 | Nayzilam, Briviact |
| Lilly USA, LLC | $328.23 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Biogen, INC. | $213.23 | 2021-2025 | Vumerity, Plegridy, Leqembi |
| Emd Serono, INC. | $195.33 | 2022-2023 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $188.33 | 2019-2022 | |
| Allergan, INC. | $171.25 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $170.24 | 2023-2025 | Nuedexta, Rexulti |
| Biohaven Pharmaceuticals, INC. | $153.65 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $150.91 | 2022 | |
| Sunovion Pharmaceuticals INC. | $142.19 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $122.10 | 2019-2020 | |
| Genzyme Corporation | $120.45 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $116.78 | 2019-2025 | Austedo Xr |
| Kyowa Kirin, INC. | $104.07 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $101.61 | 2019-2020 | |
| Sk Life Science, INC. | $87.75 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $79.98 | 2020-2021 | |
| Averitas Pharma INC. | $77.98 | 2023-2025 | Qutenza |
| Mdd US Operations, LLC | $63.53 | 2019-2020 | |
| Neurelis, INC. | $62.17 | 2020-2025 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $54.94 | 2020 | |
| Amgen INC. | $45.73 | 2021-2022 | |
| Axsome Therapeutics, INC. | $43.14 | 2025 | Symbravo |
| Jazz Pharmaceuticals INC. | $36.63 | 2022 | |
| Upsher-Smith Laboratories LLC | $24.73 | 2019 | |
| Banner Life Sciences, LLC | $21.29 | 2022 | |
| Tg Therapeutics, INC. | $18.53 | 2025 | |
| Avanir Pharmaceuticals, INC. | $15.58 | 2019 | |
| Genentech USA, INC. | $13.85 | 2025 | Ocrevus Zunovo |
| Sanofi-Aventis U.S. LLC | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasik Parmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.